Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | CD69 | Q07108 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380943 | 0.88 | CYP2C19 (0.61) | CYP2C19PTGDR2SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL8422162 | 0.87 | CYP2C19 (0.63) | CYP2C19PTGDR2SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL14501995 | 0.85 | ALDH1A1 (0.48) | CYP2C19PTGDR2SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL13757719 | 0.83 | CYP2C19 (0.74) | CYP2C19PTGDR2SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL17896571 | 0.81 | CYP2C19 (0.72) | CYP2C19PTGDR2SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL5284414 | 0.80 | PTGDR2 (0.70) | CYP2C19PTGDR2SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL1714794 | 0.80 | PTGDR2 (0.68) | PTGDR2SMN1; SMN2MAPTALDH1A1KDM4E | |
| SCHEMBL5321878 | 0.79 | CYP2C19 (0.68) | CYP2C19PTGDR2SMN1; SMN2ELANECD69 | |
| SCHEMBL4909292 | 0.79 | CYP2C19 (0.68) | CYP2C19PTGDR2SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL14076372 | 0.79 | CYP2C19 (0.68) | CYP2C19PTGDR2SMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824837-B1 | SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1824837-A1 | SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS | Pfizer, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| WO-2006051378-A1 | SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2006-05-18 | — | — | WO | disclosed |
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | CNR1, AVPR1A, OPRL1 | CYP2C19 1945/4885PTGDR2 406/4885SMN1; SMN2 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.